Abstract:Summary
Background : Helicobacter pylori infection may lead to peptic ulcer disease, and causes significant morbidity in patients with cirrhosis. The measurement of H. pylori antigens in human stools has been proposed as a valuable, non‐invasive, diagnostic tool. A number of tests have recently been commercialized. However, very few data are available on their reliability in patients with cirrhosis.
Aim : To evaluate the usefulness of three new tests — HpSA (Meridian Diagnostics Inc., Cincinnati, OH, USA), Sim… Show more
“…In the remaining patients H. pylori infection was determined by urea breath test. Gold standard for H. pylori infection was determined as follows: patients with a strongly positive urea breath test (ΔUBT > 20) [5] or a positive histology were considered treatment failures and received second‐line treatment. Patients with a weakly positive test (ΔUBT 5–20) underwent a second urea breath test to confirm persistence of the infection.…”
All monoclonal fecal tests in this series presented similar performance in the post-treatment setting. A negative test after treatment adequately predicted cure of the infection. However, nearly a third of tests were false positive, showing a poor predictive yield for persistent infection.
“…In the remaining patients H. pylori infection was determined by urea breath test. Gold standard for H. pylori infection was determined as follows: patients with a strongly positive urea breath test (ΔUBT > 20) [5] or a positive histology were considered treatment failures and received second‐line treatment. Patients with a weakly positive test (ΔUBT 5–20) underwent a second urea breath test to confirm persistence of the infection.…”
All monoclonal fecal tests in this series presented similar performance in the post-treatment setting. A negative test after treatment adequately predicted cure of the infection. However, nearly a third of tests were false positive, showing a poor predictive yield for persistent infection.
“…Among patients with liver cirrhosis [41], HpSA test showed a low sensitivity (75.4%) although the specificity was good (94.1%). In addition, two other stool antigen tests based on monoclonal antibodies showed poor results in this particular group of patients [42]. In one of the studies mentioned above [39] a new polyclonal antibody based faecal test was compared with the HpSA test and found to give comparable results.…”
Numerous studies are still published on diagnostic tests for Helicobacter pylori, essentially for noninvasive tests. The urea breath test is applied in different types of patients, and there are attempts to have quicker and simpler protocols. Stool tests using monoclonal antibodies are now evaluated while serology is still a subject of interest. The progress in PCR (multiplex PCR, real-time PCR) has also stimulated the research in this area of invasive tests, in order to get insight into virulence factors, macrolide susceptibility and to detect H. pylori in nonconventional specimens.
“…Fecal immunoassays perform far more irregularly than other methods do, and indeed the diagnostic accuracy of the different stool tests varies widely [2,3]. One of the reasons for this variation in accuracy is that the antibody composition of the tests that use polyclonal antibodies may change from batch to batch, thus presenting major intratest variability [4][5][6]. Therefore, polyclonal tests are clearly less reliable than are monoclonal tests or urea breath tests [3].…”
Amplified IDEIA Hp StAR seems to be the most accurate stool test for diagnosing H. pylori for patients with dyspeptic symptoms. The currently available in-office tests obtain slightly less reliable results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.